Barclays
KURA icon

Barclays’s Kura Oncology KURA Stock Holding History

Barclays’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.57M Sell
143,568
-10,825
-7% -$102K ﹤0.01% 2493
2026
Q1 		$1.26M Sell
154,393
-240,212
-61% -$2.06M ﹤0.01% 2615
2025
Q4 		$4.1M Buy
394,605
+17,726
+5% +$186K ﹤0.01% 2372
2025
Q3 		$3.34M Sell
376,879
-26,362
-7% -$188K ﹤0.01% 2495
2025
Q2 		$2.33M Buy
403,241
+209,267
+108% +$1.28M ﹤0.01% 2727
2025
Q1 		$1.28M Sell
193,974
-7,890
-4% -$61.5K ﹤0.01% 2951
2024
Q4 		$1.76M Buy
201,864
+36,380
+22% +$523K ﹤0.01% 2981
2024
Q3 		$3.23M Buy
165,484
+84,563
+105% +$1.71M ﹤0.01% 2454
2024
Q2 		$1.67M Sell
80,921
-22,991
-22% -$473K ﹤0.01% 2269
2024
Q1 		$2.22M Sell
103,912
-103,360
-50% -$2.01M ﹤0.01% 2474
2023
Q4 		$2.98M Buy
207,272
+52,027
+34% +$512K ﹤0.01% 2563
2023
Q3 		$1.42M Buy
155,245
+32,978
+27% +$335K ﹤0.01% 2107
2023
Q2 		$1.29M Sell
122,267
-104,848
-46% -$1.24M ﹤0.01% 2147
2023
Q1 		$2.78M Buy
227,115
+41,066
+22% +$512K ﹤0.01% 1945
2022
Q4 		$2.31M Sell
186,049
-44,493
-19% -$647K ﹤0.01% 2170
2022
Q3 		$3.15M Buy
230,542
+128,990
+127% +$1.99M ﹤0.01% 1441
2022
Q2 		$1.86M Buy
101,552
+39,063
+63% +$562K ﹤0.01% 1901
2022
Q1 		$1M Sell
62,489
-63,157
-50% -$912K ﹤0.01% 2395
2021
Q4 		$1.76M Buy
125,646
+42,711
+51% +$692K ﹤0.01% 2465
2021
Q3 		$1.55M Buy
82,935
+8,189
+11% +$154K ﹤0.01% 2515
2021
Q2 		$1.56M Sell
74,746
-61,456
-45% -$1.53M ﹤0.01% 2365
2021
Q1 		$3.85M Buy
136,202
+114,698
+533% +$3.63M ﹤0.01% 1744
2020
Q4 		$702K Sell
21,504
-98,642
-82% -$3.47M ﹤0.01% 3009
2020
Q3 		$3.68M Buy
120,146
+34,868
+41% +$770K ﹤0.01% 1614
2020
Q2 		$1.39M Buy
85,278
+49,130
+136% +$709K ﹤0.01% 2447
2020
Q1 		$360K Buy
36,148
+923
+3% +$10.6K ﹤0.01% 3843
2019
Q4 		$484K Buy
35,225
+18,176
+107% +$269K ﹤0.01% 4336
2019
Q3 		$259K Sell
17,049
-4,630
-21% -$82.4K ﹤0.01% 4770
2019
Q2 		$427K Buy
21,679
+13,683
+171% +$227K ﹤0.01% 4465
2019
Q1 		$133K Buy
+7,996
New +$123K ﹤0.01% 5134
2018
Q4 		– Sell
-12,965
Closed -$228K – 7133
2018
Q3 		$228K Buy
12,965
+7,285
+128% +$140K ﹤0.01% 4896
2018
Q2 		$103K Sell
5,680
-3,297
-37% -$55.8K ﹤0.01% 5224
2018
Q1 		$168K Buy
8,977
+3,600
+67% +$70.1K ﹤0.01% 4977
2017
Q4 		$82K Buy
5,377
+4,928
+1,098% +$72.6K ﹤0.01% 5392
2017
Q3 		$7K Buy
449
+438
+3,982% +$4.11K ﹤0.01% 6288
2017
Q2 		$0 Sell
11
-6,789
-100% -$61.8K ﹤0.01% 6787
2017
Q1 		$60K Buy
+6,800
New +$49.9K ﹤0.01% 5233

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Barclays's KURA Position: Q2 2026 in Review

Barclays reduced its Kura Oncology (KURA) stake by 7% in Q2 2026, selling an estimated $102K and leaving 143,568 shares worth $1.57M. The position accounts for ﹤0.01% of the portfolio, ranked #2493.

Barclays first reported a position in KURA in Q1 2017 and has held it in 37 quarters since. The position peaked at $4.1M in Q4 2025. 220 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • Barclays held 143,568 shares of Kura Oncology worth $1.57M as of Q2 2026.
  • Barclays sold 10,825 Kura Oncology shares in Q2 2026, an estimated $102K.
  • Kura Oncology made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #2493 holding.
  • Barclays first reported a position in Kura Oncology in Q1 2017 and has held it in 37 quarters since.
  • Barclays's Kura Oncology position peaked at $4.1M in Q4 2025.
  • 220 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.